Reimbursement and value assessment frameworks: ensuring patients’ access to asthma medicines in Ukraine

Zaliska, O.; Piniazhko, O; Ilyk, Roman; Irynchyn, Hryhoriy

doi:10.7365/jhpor.2017.1.5

Cited by 2 publications

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The legislation, HTA training for experts on the Expert committee of the Ministry of Health (MoH), and the creation of NLEM comprised the implementation of HTA in 2016. As a result of newly enacted laws, reimbursement programs for cardiovascular disorders, 2nd type diabetes (T2D), and asthma began in April 2017 [31]. According to the study's findings, the application of HTA in decision-making in Ukraine will give patients access to cutting-edge medications and ensure an open, uniform procedure for deciding which health technologies to include on regulatory lists and reimbursement schemes.…”

Section: Elucidation Of Resultsmentioning

confidence: 99%

Innovations in Ukrainian medicine: priorities, directions, and forecasts

2022

FEM

View full text Add to dashboard Cite

Aims: There is a tangible informative lack in terms of medical innovation in Ukraine. Little accessible information regarding the steps being taken to foster medical innovation in Ukraine is due to the country's ongoing conflict and the significant pressure on its healthcare sector. Such an informative gap emphasises the necessity for additional research into Ukraine's unique medical landscape. Study design: Literature review Methodology: MEDLINE, Cochrane Reviews, and Pedro were among the databases used to conduct the literature search. The conjunctions "AND" and "OR" were used with certain keywords. The articles' time range was restricted between 2018 and 2022 in order to evaluate only present recent facts. Papers discussing innovative medicine, their development, distribution or procurement were included in the inclusion criteria. Results: Most studies examined how could be achieved the access to revolutionary medicine ignoring the medicine development. The creation of innovative medications was the subject of just one study. Most of the research discussed HTA and MEA and how important they were to ensuring patients had easy access to cutting-edge medications. Legislative or economic restrictions were the only one’s present. Conclusion: It is unclear how innovative pharmaceutical development is currently progressing in Ukraine. Health Technology Assessment (HTA) and Managed Entry Agreements (MEA) are being used to improve the access to innovative medicine in Ukraine. Buying medications for chronic illnesses is simple and convenient. In order to develop and distribute new medicine in Ukraine, regulatory and economic restrictions must be removed. Scientific Novelty: This study is the first to analyse the availability or development of innovative medication, therefore it can serve as the foundation for future studies by other groups. However, it would necessitate further on-the-ground research concerning the actual situation surrounding the creation, dissemination, and acquisition of innovative medicines. The ongoing war effort may hinder this.

show abstract

Section: Elucidation Of Resultsmentioning

confidence: 99%

Innovations in Ukrainian medicine: priorities, directions, and forecasts

2022

FEM

View full text Add to dashboard Cite

show abstract

Health Technology Assessment Implementation in Ukraine: Current Status and Future Perspectives

Csanádi

Inotai

Олещук

et al. 2019

Int J Technol Assess Health Care

View full text Add to dashboard Cite

ObjectivesThe need for improving healthcare decision making by implementing health technology assessment (HTA) has been a top priority in Ukraine since 2016. This study sought to provide a tailor-made HTA implementation roadmap, drawing on insights from national stakeholders.MethodsWe conducted a survey using a questionnaire already applied in previous HTA research. We assessed the status of HTA when reforms were initiated in 2016 and examined perspectives on possible future developments among policy makers and representatives of pharmaceutical companies and patient organizations.ResultsThirty-two respondents answered the survey. Forty-eight percent of respondents were not aware of HTA training in Ukraine, but 91 percent preferred having either a graduate or postgraduate training. Experts stated that funding for HTA research and for critical appraisal of HTA submissions was limited, but in the future, they would increase funding mainly from public sources. A public HTA agency with academic support was the most preferred organizational structure. Eighty-eight percent of respondents opted for full transparency, making the HTA agency's recommendations and the related appraisal reports publicly available. A great majority of participants preferred mandating the use of local data in certain categories and indicated the importance of evaluating the transferability of international evidence. Healthcare priority and cost-effectiveness were the most important criteria for decisions, applied with a soft explicit threshold.ConclusionsUkraine is in the early phase of implementing HTA and our study provides a clear vision of national stakeholders about the future directions. In addition, learning from the experiences of other countries may help the implementation process.

show abstract

Reimbursement and value assessment frameworks: ensuring patients’ access to asthma medicines in Ukraine

Cited by 2 publications

References 2 publications

Innovations in Ukrainian medicine: priorities, directions, and forecasts

Innovations in Ukrainian medicine: priorities, directions, and forecasts

Health Technology Assessment Implementation in Ukraine: Current Status and Future Perspectives

Contact Info

Product

Resources

About